Brainomix Appoints Anna Griffin as Chief Financial Officer
Brainomix, a global leader in Al-powered imaging solutions in stroke and lung fibrosis, hasannounced the appointment of Anna Griffin as Chief Financial Officer, filing a key leadership rolewithin the company following its recent £14M Series C funding round.
Anna joins Brainomix from Mirada Medical, another successful Oxford-based medical imagingcompany, where she had worked for 15 years, progressing through a series of increasingly seniorroles, including most recently as Chief Financial & Operations Officer, Anna has extensive globalexperience, having managed Finance and Operations in the UK, Europe and the US
“We are delighted to have Anna on board, joining our Executive Leadership Team. Anna brings awealth of domain expertise in medical imaging, and has demonstrated an impressive record ofsuccessfully managing operations in both the US and Europe," said Dr Michalis Papadakis, CE0 &Co-Founder of Brainomix. “As Chief Financial Officer, Anna will play an instrumental role inpreparing the company for our next inflection point, as we accelerate commercial expansion in theUS and advance the clinical uptake of our lung fibrosis technology.
"l am very excited to be joining Brainomix at such a pivotal growth stage. l look forward to workingclosely with the leadership team and the Board as we continue our mission of delivering clinicallyimpactful Al solutions that are transforming treatment in stroke and lung fibrosis" said Anna
Griffin.
To learn more about Anna and the rest of Brainomix's Leadership Team, click here